Regen Biopharma Stock Performance
| RGBP Stock | USD 0.01 0 20.83% |
The company holds a Beta of 1.02, which implies a somewhat significant risk relative to the market. Regen BioPharma returns are very sensitive to returns on the market. As the market goes up or down, Regen BioPharma is expected to follow. At this point, Regen BioPharma has a negative expected return of -0.21%. Please make sure to check Regen BioPharma's value at risk, as well as the relationship between the daily balance of power and period momentum indicator , to decide if Regen BioPharma performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Regen BioPharma has generated negative risk-adjusted returns adding no value to investors with long positions. Even with unfluctuating performance in the last few months, the Stock's fundamental drivers remain relatively invariable which may send shares a bit higher in February 2026. The latest agitation may also be a sign of long-running up-swing for the enterprise retail investors. ...more
| Begin Period Cash Flow | 727.2 K | |
| Total Cashflows From Investing Activities | 25 K |
Regen |
Regen BioPharma Relative Risk vs. Return Landscape
If you would invest 1.30 in Regen BioPharma on October 29, 2025 and sell it today you would lose (0.54) from holding Regen BioPharma or give up 41.54% of portfolio value over 90 days. Regen BioPharma is currently does not generate positive expected returns and assumes 11.8406% risk (volatility on return distribution) over the 90 days horizon. In different words, most equities are less risky than Regen, and most traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Regen BioPharma Target Price Odds to finish over Current Price
The tendency of Regen Pink Sheet price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 0.01 | 90 days | 0.01 | about 80.98 |
Based on a normal probability distribution, the odds of Regen BioPharma to move above the current price in 90 days from now is about 80.98 (This Regen BioPharma probability density function shows the probability of Regen Pink Sheet to fall within a particular range of prices over 90 days) .
Given the investment horizon of 90 days the pink sheet has the beta coefficient of 1.02 indicating Regen BioPharma market returns are sensible to returns on the market. As the market goes up or down, Regen BioPharma is expected to follow. Additionally Regen BioPharma has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the Dow Jones Industrial. Regen BioPharma Price Density |
| Price |
Predictive Modules for Regen BioPharma
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Regen BioPharma. Regardless of method or technology, however, to accurately forecast the pink sheet market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the pink sheet market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Regen BioPharma Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Regen BioPharma is not an exception. The market had few large corrections towards the Regen BioPharma's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Regen BioPharma, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Regen BioPharma within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -0.37 | |
β | Beta against Dow Jones | 1.02 | |
σ | Overall volatility | 0 | |
Ir | Information ratio | -0.03 |
Regen BioPharma Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Regen BioPharma for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Regen BioPharma can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Regen BioPharma generated a negative expected return over the last 90 days | |
| Regen BioPharma has high historical volatility and very poor performance | |
| Regen BioPharma has some characteristics of a very speculative penny stock | |
| Regen BioPharma has a very high chance of going through financial distress in the upcoming years | |
| Regen BioPharma currently holds 1.58 M in liabilities with Debt to Equity (D/E) ratio of 1.25, which is about average as compared to similar companies. Regen BioPharma has a current ratio of 0.05, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Regen BioPharma until it has trouble settling it off, either with new capital or with free cash flow. So, Regen BioPharma's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Regen BioPharma sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Regen to invest in growth at high rates of return. When we think about Regen BioPharma's use of debt, we should always consider it together with cash and equity. | |
| Regen BioPharma currently holds about 110.99 K in cash with (606.92 K) of positive cash flow from operations. |
Regen BioPharma Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Regen Pink Sheet often depends not only on the future outlook of the current and potential Regen BioPharma's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Regen BioPharma's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 3 B | |
| Cash And Short Term Investments | 51.2 K |
Regen BioPharma Fundamentals Growth
Regen Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Regen BioPharma, and Regen BioPharma fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Regen Pink Sheet performance.
| Return On Asset | -0.76 | |||
| Profit Margin | 6.09 % | |||
| Operating Margin | (2.96) % | |||
| Current Valuation | 22.4 M | |||
| Shares Outstanding | 5.05 B | |||
| Price To Sales | 89.73 X | |||
| Revenue | 235.52 K | |||
| EBITDA | 2.44 M | |||
| Cash And Equivalents | 110.99 K | |||
| Total Debt | 1.58 M | |||
| Debt To Equity | 1.25 % | |||
| Book Value Per Share | (0) X | |||
| Cash Flow From Operations | (606.92 K) | |||
| Total Asset | 559 K | |||
| Retained Earnings | (17.78 M) | |||
| Current Asset | 171 K | |||
| Current Liabilities | 649 K | |||
About Regen BioPharma Performance
Assessing Regen BioPharma's fundamental ratios provides investors with valuable insights into Regen BioPharma's financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Regen BioPharma is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
Regen BioPharma, Inc. focuses on the development of regenerative medical applications in the United States. Regen BioPharma, Inc. was incorporated in 2012 and is based in La Mesa, California. Regen Biopharma operates under Biotechnology classification in the United States and is traded on OTC Exchange.Things to note about Regen BioPharma performance evaluation
Checking the ongoing alerts about Regen BioPharma for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Regen BioPharma help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Regen BioPharma generated a negative expected return over the last 90 days | |
| Regen BioPharma has high historical volatility and very poor performance | |
| Regen BioPharma has some characteristics of a very speculative penny stock | |
| Regen BioPharma has a very high chance of going through financial distress in the upcoming years | |
| Regen BioPharma currently holds 1.58 M in liabilities with Debt to Equity (D/E) ratio of 1.25, which is about average as compared to similar companies. Regen BioPharma has a current ratio of 0.05, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Regen BioPharma until it has trouble settling it off, either with new capital or with free cash flow. So, Regen BioPharma's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Regen BioPharma sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Regen to invest in growth at high rates of return. When we think about Regen BioPharma's use of debt, we should always consider it together with cash and equity. | |
| Regen BioPharma currently holds about 110.99 K in cash with (606.92 K) of positive cash flow from operations. |
- Analyzing Regen BioPharma's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Regen BioPharma's stock is overvalued or undervalued compared to its peers.
- Examining Regen BioPharma's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Regen BioPharma's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Regen BioPharma's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Regen BioPharma's pink sheet. These opinions can provide insight into Regen BioPharma's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Regen Pink Sheet Analysis
When running Regen BioPharma's price analysis, check to measure Regen BioPharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Regen BioPharma is operating at the current time. Most of Regen BioPharma's value examination focuses on studying past and present price action to predict the probability of Regen BioPharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Regen BioPharma's price. Additionally, you may evaluate how the addition of Regen BioPharma to your portfolios can decrease your overall portfolio volatility.